Symptomatic hypophosphataemia after intravenous iron therapy: An underrated adverse reaction

Endocrinology, Diabetes and Metabolism Case Reports

Volumn 2019, Issue 1, 2019, Pages

  Ifie, Eseoghene ^a   Oyibo, Samson O ^b   Joshi, Hareesh ^b   Akintade, Olugbenro O ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b PETERBOROUGH CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; POLYFUSOR; SODIUM DIHYDROGEN PHOSPHATE;

ADULT; AMINOACIDURIA; ARTICLE; CASE REPORT; CAUCASIAN; CLINICAL ARTICLE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; EFFERVESCENT TABLET; EMERGENCY WARD; EPIGASTRIC DISCOMFORT; FATIGUE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPOPHOSPHATEMIA; INDIGESTION; IRON DEFICIENCY; IRON THERAPY; KIDNEY TUBULE DISORDER; MEDICAL HISTORY; MEDICATION COMPLIANCE; MUSCLE CRAMP; NAUSEA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SYMPTOM; TABLET; THORAX PAIN; UTERUS BLEEDING;

EID: 85076220249     PISSN: None     EISSN: 20520573     Source Type: Journal    
DOI: 10.1530/EDM-19-0065     Document Type: Article

References (11)

1. Moore RA, Gaskell H, Rose P & Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders 2011 11 4. (https://doi.org/10.1186/1471-2326-11-4)
2. Shamida T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T. Cloning and characterisation of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 2001 98 6500–6505. (https://doi.org/10.1073/pnas.101545198)
3. Blazevic A, Hunze J & Boots JMM. Severe hypophosphataemia after intravenous iron administration. Netherlands Journal of Medicine 2014 72 49–53.
4. Anand G & Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Reports 2017 2017 bcr2016219160. (https://doi.org/10.1136/bcr-2016-219160)
5. Klein K, Asaad S, Econs M & Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Reports 2018 2018 bcr-2017-222851. (https://doi.org/10.1136/bcr-2017-222851)
6. Hardy S & Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. International Journal of Rheumatology 2015 2015 468675. (https://doi. org/10.1155/2015/468675)
7. Anderson C, Krska J, Murphy E, Avery A & Yellow Card Study Collaboration. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. British Journal of Clinical Pharmacology 2011 72 806–822. (https://doi.org/10.1111/j.1365-2125.2011.03990.x)
8. Wolf M, Koch TA & Bregman DB. Effects of iron deficiency anaemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of Bone and Mineral Research 2013 28 1793–1803. (https://doi.org/10.1002/jbmr.1923)
9. Barish CF, Koch T, Butcher A, Morris D & Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia 2012 2012 1–9. (https://doi.org/10.1155/2012/172104)
10. Auerbach M, Chertow GM & Rosner M. Ferumoxytol for the treatment of iron deficiency anemia. Expert Review of Hematology 2018 11 829–834. (https://doi.org/10.1080/17474086.2018.1518712)
11. Kalra PA & Bhandari S. Safety of intravenous iron use in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2016 25 529–535. (https://doi.org/10.1097/MNH.0000000000000263)